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Introduction
41
With the rapid growth of aging populations worldwide, cognitive decline and dementia are 42 becoming an increasing burden not only on patients and their families, but also on national healthcare 43 systems. Owing to the lack of an effective therapy for dementia, preventive approaches are receiving 44 increasing attention. Recent epidemiological studies suggest that consumption of certain dairy 45 products reduces the risk of cognitive decline in the elderly and may prevent Alzheimer's disease.
46
For example, Camfield et al. (Camfield et al., 2011) suggested that specific ingredients, especially bioactive peptides, might be beneficial for promoting healthy brain function during aging.
48
Crichton et al. (Crichton et al., 2010) reported that individuals who consumed low-fat dairy products,
49
including yogurt and cheese, once a week had a higher cognitive function than those who did not. A 50 survey-based study of self-reported health information found that consumption of low-fat dairy 51 products was associated with increased memory recall, increased social functioning and decreased 52 stress (Ozawa et al., 2013; Ozawa et al., 2014) . Ozawa et al. (Ozawa et al., 2013; Ozawa et al., 2014) 53 surveyed more than 1000 Japanese subjects who were living in the community, aged 60-79 years and 54 free from dementia to investigate their dietary patterns and any potential association with reduced risk 55 of dementia. They concluded that inclusion of milk or fermented dairy products in the diet reduces the 56 risk of dementia in the general Japanese population. In a clinical trial, Ogata et al. (Ogata et al., 2016) 57 investigated the association between intake of dairy products and short-term memory and found that 58 intake of dairy products is highly associated with better short term memory. In addition, Markus et (Xing et al., 2014) . These studies have encouraged us to search for peptides from milk proteins 75 that can improve cognitive decline and boost memory function. In the present study, we screened 76 peptides generated from whey proteins during the cheese manufacturing process for their ability to cognitive function, especially memory function. 
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88
and rats were euthanized by exsanguination from the abdominal aorta after anesthesia with isoflurane.
89
Mice under 3 months of age were fed with a standard purified rodent growth diet (AIN-93G, Oriental
90
Yeast, Tokyo, Japan), and those over 3 months with a maintenance diet (AIN-93M, Oriental Yeast).
92
Preparation of peptide samples from whey and peptide analysis
93
To prepare peptide products, 5% (w/v) whey protein (Daiichi Kasei, Tochigi, Japan) was 94 dissolved in 0.05 M Tris buffer (pH 7.5) and digested with 10 different enzymes (0.125% (w/v), Table   95 1) at 50 ℃ for 4 hours. After enzyme reaction, the samples were filtered through a 10-kDa 96 membrane to remove undigested proteins and the enzymes. The filtered samples were used in an in 97 vivo evaluation. Selected products digested with enzyme from Aspergillus melleus and Bacillus 98 stearothermophilus were used in subsequent studies.
99
The digested products were fractionated by solid-phase extraction. Each digested product was 100 dissolved in water and applied to a Sep-Pak C18 cartridge column (Nihon Waters, Tokyo, Japan).
101
Bound compounds were eluted with 20%, 40%, 60%, 80%, and 100% methanol. Further 
108
were identified by a combination of LC/MS and N-terminal Edman sequencing (data not shown). The 109 identified peptides were then synthesized (Eurofins, Tokyo, Japan) and their activity was evaluated again. Gly-Thr-Trp-Tyr was purchased from Bachem (Bubendorf, Switzerland).
112
Spontaneous alternation test
113
The Y-maze is a three-arm maze with equal angles between all arms (25 cm long × 5 cm wide × 114 20 cm high). The maze walls were constructed from dark black, polyvinyl plastic. Each mouse was 115 initially placed in one arm, and the sequence and number of arm entries were counted for 8 minutes.
116
The alternation score (%) for each mouse was defined as the ratio of the actual number of alternations 117 to the possible number (defined as the total number of arm entries minus two) multiplied by 100 as 
126
In some experiments, mice were given 0.85 mg/kg (-) scopolamine hydrobromide trihydrate 
140
pyramids and a golf ball (4.5 cm diameter) were used. In all trials, the objects were placed 7.5 cm 141 apart from the corner of the box. In the acquisition trial, each mouse was allowed to explore the box 142 with the two objects for 10 min at 1 hour after oral administration of the test sample. Twenty-four 143 hours after the acquisition trial, the mouse was allowed to explore the box with the novel and familiar 
168
To measure MAO inhibitory activity in vivo, 6-week-old ICR male mice were orally given 169 0, 1 or 10 mg/kg GTWY peptide for 5 days. At 1 hour after the last administration, the brain tissue 170 was obtained and homogenized with TBS buffer. The MAO-B activity was measured by using the 171 monoamine oxidase assay kit as described above. 
180
For ECD, the applied voltage was 750 mV vs an Ag/AgCl reference electrode.
182
Quantification of Gly-Thr-Trp-Tyr peptide in fermented products
183
For sample preparation, commercially available cheeses (Taleggio, Mascarpone, Cheddar, Feta, Gouda) were extracted by the method of Bütikofer et al. (Bütikofer et al., 2007) with slight 186 modifications. In brief, 1 g of cheese was homogenized in 5 ml of distilled water using a Polytron 187 homogenizer (IKA Japan K.K., Osaka Japan) and incubated in a water bath (TAITEC, Saitama,
Commercially available yogurts were diluted with an equal amount of distilled water, and whey 192 peptide samples were dissolved in distilled water at 5 % (w/w) before centrifugation at 14000 x g and 193 4 °C. The supernatants were filtered through an Amicon Ultra 10 K device with centrifugation at 194 14000 x g and 4 °C.
195
To quantify by using LC/MS/MS, a 4000 QTRAP mass spectrometer (ABSciex, MA, USA)
196
coupled to an HPLC system (Agilent 1200 series, Agilent Technologies, CA, USA) was used to 
203
resolution both set to unit; curtain gas, 40; ion spray voltage, 5000 V; temperature, 600 °C; ion source 204 gas 1 set to 50 °C; ion source gas 2 set to 80 °C; dwell time, 150 ms; and declustering potential, 111 V.
205
All samples were diluted in 0.1 % formic acid and 5 % acetonitrile. Analyst 1.6.2 software was used to 206 control both the LC system and 4000 QTRAP. MRM ion transitions were optimized for GTWY: 
216
Effect of digested whey peptides on a mouse model of scopolamine-induced amnesia
217
Amnesia induced by the muscarinic antagonist scopolamine has been widely used to test therapeutic 218 drugs for memory impairment. As a positive control, donepezil, an acetylcholineesterase inhibitor,
219
improved spontaneous alternation of the ICR mice at 6-week-old in the Y-maze test (Fig. 1a) ,
220
indicating that this test is useful to screen for compounds that improve memory performance in the 221 amnesia mouse model.
222
To identify the peptides in dairy products responsible for improving memory performance,
223
we tested 10 randomly selected proteases from effective microbes (Table 1) (Fig. 1c) were separated by HPLC, and the amino acid sequences of the peptides were determined (Fig. 2a) .
240
The enzymes used in this experiment were mixtures of various proteases and peptidases, which (Fig. 2b-l) . Among the peptides from whey proteins digested by protease P [amano] 246 3SD, Gly-Thr-Trp-Tyr (GTWY) showed an improvement in memory function (Fig. 2d) , whereas
247
Ala-Leu-Asn-Glu-Asn-Lys-Val-Leu (ALNENKVL, Fig. 2b 
263
Administration of GTWY peptide (50 and 500 µg/kg) led to a significant improvement in 264 spontaneous alternation (Fig. 3a) and no change in arm entries (Fig. 3b) , and led to longer staying 265 times at the proximal novel object as compared with vehicle-administered control (Fig. 3c) . The 266 discrimination index in the novel object recognition test was also significantly improved i in mice 267 treated with GTWY peptide (Fig. 3d) . Thus, GTWY peptide administration improved not only spatial 
288
peptide was administered to SD rats and radioactivity was measured in the blood at various time
289
points. 14 C-GTWY peptide was incorporated into blood as early as 2 min after oral administration and 290 its concentration reached a maximum at 4 hours (Table 2a) . At 2 hour after oral administration, the 291 concentration of 14 C-GTWY peptide in the blood was 76.3% of C max (Table 2a ). The tissue 292 distribution of the radioactivity at 1 hour after oral administration showed that the ratio of tissue to 293 plasma concentration was 0.32 in the hippocampus and 0.39 in the cerebral cortex (Table 2b ). There 
302
Because the effective dipeptide in digested whey proteins comprises Trp and Tyr and is a source of 303 monoamine, we investigated whether dopamine is involved in the rescue effects by GTWY peptide.
304
First, we examined the amount of dopamine (DA) and its metabolites in the brain of ICR mice at 1 305 hour after a single administration of 1 or 10 mg/kg GTWY peptide. The hippocampal DA level
306
increased approximately 5-fold relative to the control after administration of 10 mg/kg of GTWY 307 peptide (Fig. 5a ). However, the levels of two DA metabolites, 3,4-dihydroxyphenylacetic acid
308
(DOPAC) and homovanillic acid (HVA), did not change after GTWY peptide treatment ( Fig. 5b and   309 c). The ratio of metabolites to DA was decreased by GTWY peptide treatment (Fig. 5d) , raising the 310 possibility that the rate of DA metabolism was decreased by GTWY peptide treatment. These changes
311
of dopamine and the ratio of its metabolite (DOPAC+HVA/DA) by GTWY peptide were in 312 accordance with those in the mice with amnesia induced by scopolamine ( Fig. 5e and f, respectively).
314
Monoamine oxidase activity
315
Next, the effects of GTWY peptide and WY dipeptide on monoamine oxidase (MAO) were tested in 316 vitro. Treatment with 1 mM GTWY peptide and WY dipeptide led to 56% and 67% inhibition of 317 MAO-B activity, respectively, but neither GTWY peptide nor WY dipeptide had an effect on MAO-A 318 activity ( Fig. 6a and b) . Oral administration of GTWY peptide also inhibited MAO-B activity in the 319 brain of ICR mice (Fig. 6c) . These results suggest that the increase in DA caused by GTWY peptide 320 treatment is due to the inhibition of MAO-B activity. In the next experiment, the involvement of DA
321
in the memory improvement of GTWY peptide was investigated using dopamine receptor antagonist.
323
Inhibition of the dopamine receptor attenuates the GTWY peptide-induced memory improvement
324
To understand the involvement of increased DA level by GTWY peptide-treatment in the M A N U S C R I P T
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14
antagonist attenuated the improvement in spontaneous alternation caused by GTWY peptide 328 administration (Fig. 7) , suggesting that the dopaminergic neuronal system is involved in the memory 
333
Epidemiological studies have reported that intake of fermented dairy products is beneficial for the 334 prevention of cognitive decline in the elderly (Camfield et al., 2011; Ozawa et al., 2013) . Our 335 previous study demonstrated that Camembert cheese, a dairy product fermented with fungi, has 336 preventive effects on Alzheimer's disease pathology in 5xFAD model mice (Ano et al., 2015b) .
337
Collectively, these studies strongly suggest that a diet of fermented dairy products is beneficial in the 338 prevention of the age-related cognitive decline that leads ultimately to dementia. In the present study,
339
we screened for components of fermented dairy products that prevent cognitive decline by using the 
347
WY plays a key role in the prevention of age-related cognitive decline.
348
We also showed that GTWY peptide, one of the WY-containing peptides, penetrates the brain, Alzheimer's disease (Borroni et al., 2017; Wang et al., 2016) and sembragiline, a MAO-B selective
358
inhibitor, was found to protect against neuronal loss and to reduce ROS formation and astrogliosis 359 (Borroni et al., 2017) . Those reports suggest that WY-containing peptides from dairy products may 360 exert their beneficial effect on the prevention of age-related cognitive decline by increasing the levels 361 of DA in the brain.
362
We determined the amount of GTWY peptide present in dairy products by LC/MS/MS. GTWY 
375
which is the main protein in whey (accounting for ~50% of total whey protein).
376
In summary, present study identified WY-related peptides as responsible components in dairy 377 products to improve memory function and age-related cognitive decline. Effective intake of GTWY 
415
Gly-Tyr-Gly-Gly-Val-Ser-Leu-Pro (GYSSVSLP), Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile
416
(KPTPEGDLEIL), Thr-Trp-Tyr-Ser (TWYS), *p=0.0459, Thr-Trp-Tyr (TWY), *p=0.0311,
417
Val-Ala-Gly-Thr-Trp-Tyr-Ser (VAGTWYS), *p=0.0355, Val-Ser-Leu-Pro-Glu-Tr (VSLPEW),
418
*p=0.0416 and Trp-Tyr (WY), *p=0.0153, respectively, on spontaneous alternations. Data represent 
